A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The firm will develop an assay to detect and monitor Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7 th from 4:05PM – 4:35PM ET.

Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, on March 31, 2025. Dr. Genova ...

PhaseV, a leader in AI/ML-driven clinical development, announced today that it will demonstrate new capabilities of its platform for clinical trials at the upcoming Chief Medical Officer (CMO) Summit ...

Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~ ~ Interim Analysis from MAINSAIL Study Reinforces Safety ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Stäubli Robotics in collaboration with a prominent pharmaceutical company has developed a mobile robot for use in Grade A/B/C/D cleanrooms. A cross-functional team ...

“Considering the important unmet medical need, we are currently exploring all available options to make Kizfizo available to the paediatric patients,” said Laurent Martin, chief pharmaceutical affairs ...

Tonix Pharmaceuticals (TNXP) announced it has been awarded a grant from the Medical CBRN Defense Consortium, MCDC, to support the development of TNX-801. MCDC is a consortium of industrial ...